Kuehn Law Encourages Investors of Replimune Group, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - September 9, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Replimune Group, Inc. (NASDAQ: REPL) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Replimune Group caused the company to misrepresent or fail to disclose that (1) insiders recklessly overstated the IGNYTE trial's prospects, given material issues that insiders knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

If you currently own REPL and purchased prior to November 22, 2024 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265680